Analyzing Time-to-Event Data Cox Proportional Hazards Regression

Slides:



Advertisements
Similar presentations
High Resolution studies
Advertisements

The analysis of survival data in nephrology. Basic concepts and methods of Cox regression Paul C. van Dijk 1-2, Kitty J. Jager 1, Aeilko H. Zwinderman.
The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,
Residuals Residuals are used to investigate the lack of fit of a model to a given subject. For Cox regression, there’s no easy analog to the usual “observed.
Surviving Survival Analysis
Survival Analysis. Key variable = time until some event time from treatment to death time for a fracture to heal time from surgery to relapse.
X Treatment population Control population 0 Examples: Drug vs. Placebo, Drugs vs. Surgery, New Tx vs. Standard Tx Let X = decrease (–) in cholesterol.
Survival Analysis In many medical studies, the primary endpoint is time until an event occurs (e.g. death, remission) Data are typically subject to censoring.
Statistical Analysis SC504/HS927 Spring Term 2008
If we use a logistic model, we do not have the problem of suggesting risks greater than 1 or less than 0 for some values of X: E[1{outcome = 1} ] = exp(a+bX)/
Controlling for Time Dependent Confounding Using Marginal Structural Models in the Case of a Continuous Treatment O Wang 1, T McMullan 2 1 Amgen, Thousand.
Survival Analysis-1 In Survival Analysis the outcome of interest is time to an event In Survival Analysis the outcome of interest is time to an event The.
Survival Analysis. Statistical methods for analyzing longitudinal data on the occurrence of events. Events may include death, injury, onset of illness,
Introduction to Survival Analysis October 19, 2004 Brian F. Gage, MD, MSc with thanks to Bing Ho, MD, MPH Division of General Medical Sciences.
Departments of Medicine and Biostatistics
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Introduction to Survival Analysis
Chapter 11 Survival Analysis Part 3. 2 Considering Interactions Adapted from "Anderson" leukemia data as presented in Survival Analysis: A Self-Learning.
PH6415 Review Questions. 2 Question 1 A journal article reports a 95%CI for the relative risk (RR) of an event (treatment versus control as (0.55, 0.97).
Proportional Hazard Regression Cox Proportional Hazards Modeling (PROC PHREG)
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
Assessing Survival: Cox Proportional Hazards Model Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 12: Multiple and Logistic Regression Marshall University.
Biostat Didactic Seminar Series Analyzing Binary Outcomes: Analyzing Binary Outcomes: An Introduction to Logistic Regression Robert Boudreau, PhD Co-Director.
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Introduction to Survival Analysis August 3 and 5, 2004.
Correlation, Regression Covariate-Adjusted Group Comparisons
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
NASSER DAVARZANI DEPARTMENT OF KNOWLEDGE ENGINEERING MAASTRICHT UNIVERSITY, 6200 MAASTRICHT, THE NETHERLANDS 22 OCTOBER 2012 Introduction to Survival Analysis.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
Assessing Survival: Cox Proportional Hazards Model
Biostat Didactic Seminar Series Correlation and Regression Part 2 Robert Boudreau, PhD Co-Director of Methodology Core PITT-Multidisciplinary Clinical.
INTRODUCTION TO SURVIVAL ANALYSIS
HSRP 734: Advanced Statistical Methods July 17, 2008.
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
April 4 Logistic Regression –Lee Chapter 9 –Cody and Smith 9:F.
Assessing Binary Outcomes: Logistic Regression Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Research Techniques Made Simple: Multivariable Analysis Marlies Wakkee Loes Hollestein Tamar Nijsten Department of Dermatology, Erasmus University Medical.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.
Tim Wiemken PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville, Kentucky Confounding.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Advanced Statistics for Interventional Cardiologists.
1 Multivariable Modeling. 2 nAdjustment by statistical model for the relationships of predictors to the outcome. nRepresents the frequency or magnitude.
Satistics 2621 Statistics 262: Intermediate Biostatistics Jonathan Taylor and Kristin Cobb April 20, 2004: Introduction to Survival Analysis.
Biostatistics Case Studies 2014 Youngju Pak Biostatistician Session 5: Survival Analysis Fundamentals.
Instrument design Essential concept behind the design Bandit Thinkhamrop, Ph.D.(Statistics) Department of Biostatistics and Demography Faculty of Public.
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 13: Multiple, Logistic and Proportional Hazards Regression.
SURVIVAL ANALYSIS PRESENTED BY: DR SANJAYA KUMAR SAHOO PGT,AIIH&PH,KOLKATA.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Structured Physical Activity on Prevention.
Carolinas Medical Center, Charlotte, NC Website:
An introduction to Survival analysis and Applications to Predicting Recidivism Rebecca S. Frazier, PhD JBS International.
April 18 Intro to survival analysis Le 11.1 – 11.2
Survival curves We know how to compute survival curves if everyone reaches the endpoint so there is no “censored” data. Survival at t = S(t) = number still.
Survival Analysis: From Square One to Square Two Yin Bun Cheung, Ph.D. Paul Yip, Ph.D. Readings.
Tests for time-to-event outcomes (survival analysis)
Clinical outcome after SVR: Veterans Affairs
Statistics 103 Monday, July 10, 2017.
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
EPID 799C, Lecture 22 Wednesday, Nov. 14, 2018
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Heart failure.
Combined predictor Selection for Multiple Clinical Outcomes Using PHREG Grisell Diaz-Ramirez.
Comparison of Baseline Characteristics by Primary End Point
Presentation transcript:

Analyzing Time-to-Event Data Cox Proportional Hazards Regression Survival Analysis and Cox Proportional Hazards Regression Robert Boudreau, PhD Co-Director of Methodology Core PITT-Multidisciplinary Clinical Research Center for Rheumatic and Musculoskeletal Diseases

Effect of acyclovir on time to resolution of postherpetic neuralgia Spruance SL, Reid JE, Grace M, Samore M. Hazard Ratio in Clinical Trials. Antimicrob Agents and Chemotherapy Aug 2004:2787-2792.

Flow chart for regression models Outcome variable continuous or dichotomous? continuous dichotomous Predictor variable categorical? Time-to-event available ? No Yes (e.g. groups) No Yes Multiple linear regression ANCOVA Multiple logistic regression Cox proportional hazards regression

Effect of acyclovir on time to resolution of postherpetic neuralgia Event: Resolution of Herpes Zoster Pain  Time-to-event also available Statistical Modeling Approaches Logistic Regression: Would do separate rate comparisons at distinct timepoints  % with Pain Resolution by 60days, by 120 days … Cox Proportional Hazards Regression:  Comparison of survival curves across all timepoints > Uses more information: Event (Yes/No), Time-to-event > More powerful in identifying systematic differences

Examples Compare MTX+Enbrel vs MTX+Humira Time until Remission Time until ACR 20/50/70 Time until DAS drop > 1.2 Longitudinal cohort study (on aging) Time until participant develops mobility limitation Time until participant has CVD event Time until mortality event

Censoring Generally, three reasons why censoring might occur: A subject does not experience the event before the study ends A person is lost to follow-up during the study period A person withdraws from the study These are all examples of right-censoring

Censoring  Most typical to consider start of time-to-event “clock” as t=0 Censored Non-Events o o

Life Tables

Life Tables

Life Tables 146-30 Censored observations are counted in the denominator of those “at risk” until they are censored

Life Tables 146-30 Censored observations are counted in the denominator of those “at risk” until they are censored

Survival Curve

Kaplan-Meier Survival Curve Generalization of Life Table method Assumes (i.e. can handle) continuous event times Updates “at risk” denominator at each event or censor timepoint

400 meter walk time in elderly predicts mobility limitation Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, Pahor M, Satterfield S, Brach JS, Studenski SA, Harris TB. Association of Long Distance Corridor Walk Performance with Mortality, Cardiovascular Disease, Mobility Limitation, and Disability. JAMA 2006;295:2018-2026. Event: Persistent Mobility Limitation: 2 consecutive reports (6 month contacts) of having any self-reported difficulty walking a quarter of a mile or climbing stairs

% of Women With Mobility Limitation by Quartile of Baseline 400m Walk Time Lowest times (Fastest Pace)

Proportional Hazards Model Example: Compare Treatment to Control Group Dummy variable for group (random) assignment: Z= 0 if control group = 1 if treatment group Survival Curves (group specific) Control Treatment

Effect of acyclovir on time to resolution of postherpetic neuralgia

Hazard Ratio (HR) Example: Compare Treatment to Control Group Survival Curves (group specific) Control Treatment HR = (same relationship to regression coeff “beta” as OR in logistic regression)

Cox Proportional Hazards Regression proc phreg data=acyclovir; model time*event(0)=drug; run; * event=0 if censored (non-event) * =1 if event (resolution of pain) HR = exp( 0.77919) = 2.180 (acyclovir vs placebo)

Cox PH Regression Adjusted for Age proc phreg data=acyclovir; model time*pain_resolved(0)=drug age; run; Adjusted HR = exp( 0.94108) = 2.563 (acyclovir vs placebo) Age HR=1.096 => Increasing “pain resolve” response with age

400 meter walk time in elderly predicts mobility limitation Note: “Completed the 400m walk” is the referent group here

400 meter walk time (continuous) predicts mortality, CVD and mobility limitation Of those who completed 400 meters, each additional minute of performance time was associated with an adjusted HR of HR= 1.29 (95% CI, 1.12-1.48) for mortality HR= 1.20 (95% CI, 1.01-1.42) for incident cardiovascular disease HR= 1.52 (95% CI, 1.41-1.63) for mobility limitation

400 meter walk time vs mortality (best vs worst quartile) After adjusting for potential confounders, those in the poorest quartile of functional capacity (walk time > 362 seconds) had a higher risk of death over 6 years than those in the best quartile (walk time < 290 seconds).  Adjusted HR = 3.23; 95% CI, 2.11-4.94; P .001).

Thank you ! Any Questions? Robert Boudreau, PhD Co-Director of Methodology Core PITT-Multidisciplinary Clinical Research Center for Rheumatic and Musculoskeletal Diseases